# Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

> **NCT03043989** · PHASE1 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 4 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Cabazitaxel
- **DRUG:** Clarithromycin

## Key facts

- **NCT ID:** NCT03043989
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-21
- **Primary completion:** 2019-07-26
- **Final completion:** 2019-07-26
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03043989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03043989, "Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03043989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*